Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

NCT06690476 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Dose escalation(IPM514 monotherapy)
DRUG: Dose expansion (IPM514 combined with tislelizumab)
DRUG: Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)

Sponsor

Peking University